• Type of Event: This was an earnings conference call to discuss the company's financial performance for the second quarter (Q2) and first half (H1) of the financial year 2026-27 (FY27).
  • Date and Time: The call was held on Monday, 2nd November 2026. A specific start time was not mentioned in the transcript.
  • Purpose: The stated purpose was to provide an overview of the recently announced financial results, discuss business performance, and provide updates on strategic initiatives.
  • Management Participants: The following management representatives from IOL Chemicals and Pharmaceuticals Limited were present:
  • Mr. Pardeep Kumar Khanna – Chief Financial Officer
  • Mr. Abhay Raj Singh – Senior Vice President and Company Secretary
  • Mr. Kushal Kumar Rana – Director Works
  • Mr. Rakesh Mahajan – Financial Advisor and Strategic Head

The call was moderated by Mr. Vaibhav Vijaywargiya from MUFG Investor Relations.

  • Financial Period Discussed: The call primarily focused on the financial results for Q2 FY27 (Quarter ended September 2026) and H1 FY27 (Six months ended September 2026).
  • Forward-Looking Statements & Strategic Themes: The management provided a strategic update and forward-looking commentary. Key themes included:
  • Financial Guidance: The company expects full-year FY27 revenue growth to be over 25% with an EBITDA margin of 14-15%.
  • Growth Initiatives: Three new manufacturing projects were announced with a total investment of INR 500 crore to be funded through internal accruals:

1. Expansion of ibuprofen capacity from 12,000 MTPA to 18,000 MTPA (Target commissioning: FY28).

2. Establishment of a formulation CDMO facility with a capacity of 1,500 million tablets/year (Target commissioning: FY27).

3. A dedicated specialty chemicals toll manufacturing facility for a global customer (Target commissioning: November 2026).

  • Operational Focus: Priorities include scaling the diversified API portfolio, improving operational efficiencies, and strengthening international market presence.
  • Regulatory & Compliance: The transcript was filed pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. A standard disclaimer was read at the beginning of the call stating that it contained forward-looking statements based on current beliefs and expectations, subject to risks and uncertainties.

Additional Notes Section

  • The document is the complete transcript of the earnings call, which includes the management's opening remarks and the full question-and-answer session with analysts.
  • Financial Data Disclosure: The announcement itself (the covering letter) did not contain financial data. However, the enclosed transcript did contain extensive financial figures from the recently announced results, including:
  • Q2 FY27 Revenue: INR 795 crore (up ~40% YoY)
  • H1 FY27 Revenue: INR 1,551 crore (up ~39% YoY)
  • Q2 FY27 EBITDA: INR 115 crore (up ~80% YoY); Margin: 14.4% (up 321 bps YoY)
  • H1 FY27 EBITDA: INR 227 crore (up ~70% YoY); Margin: 14.5%
  • Q2 FY27 PAT: INR 65 crore (up ~117% YoY)
  • H1 FY27 PAT: INR 130 crore (up ~100% YoY)
  • Export Contribution (H1 FY27): ~28% of revenue
  • Planned Capex for FY27: INR 250 crore (half already spent in H1)
  • The transcript also contained numerous operational updates, including the receipt of a GMP certification for the formulation CDMO facility and a CEP from EDQM for Fenofibrate-Process II.